Items Tagged ‘ADXS-PSA’

August 27th, 2014

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer


Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer. Both ADXS-PSA and pembrolizumab are investigational members of […]

View full entry

Tags: ADXS-PSA, Metastatic Stage IV (D) Prostate Cancer, News, pembrolizumab, Prostate Cancer, Refactory/Recurrent Prostate Cancer